Lv1
60 积分 2022-07-11 加入
RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
4天前
求助中
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
3个月前
已完结
Human HDAC6 senses valine abundancy to regulate DNA damage
6个月前
已完结
Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer
6个月前
已完结
Targeting cancer with small-molecule pan-KRAS degraders
7个月前
已完结
Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer
9个月前
已完结
The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis
9个月前
已完结
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
9个月前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
10个月前
已完结
皖公网安备34019202002308
